X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
SGR-1505 is a mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) inhibitor, small molecule drug candidate. It is being evaluated for the treatment of relapsed/refractory B-cell malignancies.
Lead Product(s): SGR-1505
Therapeutic Area: Oncology Product Name: SGR-1505
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 20, 2024
Details:
Under the terms of the agreement, Schrödinger will be responsible for drug design through lead optimization and Otsuka will be responsible for all other drug discovery and clinical development activities, with the aim of rapidly expanding Otsuka's R&D pipeline.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Undisclosed
Recipient: Otsuka Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 10, 2023
Details:
The data presented demonstrate that SGR-2921 exhibits strong anti-tumor activity in vivo across multiple acute myeloid leukemia (AML) models, including cell-derived xenograft models, as a monotherapy and in combination with standard of care agents.
Lead Product(s): SGR-2921,Undisclosed
Therapeutic Area: Oncology Product Name: SGR-2921
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2022
Details:
Schrödinger is advancing SGR-2921 through investigational new drug (IND)-enabling studies with plans to initiate a Phase 1 trial in patients with relapsed/refractory acute myeloid leukemia (AML) in the second half of 2023.
Lead Product(s): SGR-2921,Undisclosed
Therapeutic Area: Oncology Product Name: SGR-2921
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2022
Details:
Under the terms of the agreement, Schrödinger will be responsible for the discovery and optimization of small molecule compounds addressing the target. Lilly will be responsible for the completion of preclinical development, clinical development and commercialization.
Lead Product(s): Undisclosed
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: $425.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration October 06, 2022
Details:
SGR-1505 is a mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) inhibitor that was discovered using Schrödinger’s proprietary physics-based computational platform.
Lead Product(s): SGR-1505
Therapeutic Area: Oncology Product Name: SGR-1505
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 28, 2022
Details:
Schrodinger has identified, highly selective Wee1 inhibitors with optimized physicochemical properties show strong pharmacodynamic responses and anti-tumor activity in preclinical models also increased DNA damage and mitosis in tumor cells leading to tumor regression in vivo.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2022
Details:
The collaboration has generated numerous promising therapeutic candidates, including small molecule inhibitors of acetyl-CoA carboxylase and TYK2, which are now in the clinic, and a MAP4K1/HPK1 inhibitor, which Nimbus plans to advance to the clinic later this year.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Nimbus Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 12, 2021
Details:
The agreement provides Schrödinger with pipeline expansion opportunities in precision oncology and co-development and co-commercialization rights in the U.S.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Zai Lab
Deal Size: $338.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration August 04, 2021
Details:
The collaboration combines Schrödinger’s physics-based computational platform and drug discovery capabilities with BMS's expertise in development and commercialization to advance small molecule therapeutics for targets in oncology, immunology, and neurological disorders.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Bristol Myers Squibb
Deal Size: $2,755.0 million Upfront Cash: $55.0 million
Deal Type: Collaboration November 23, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
